Loading clinical trials...

Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause

Combined Oral Contraceptives, Progestogens, and Non-steroidal Anti-inflammatory Drugs for Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause

NCT02943655•Assiut University

View on ClinicalTrials.gov

Summary

Abnormal uterine bleeding encompasses abnormalities in the regularity, duration of flow, frequency, and/or blood flow volume relative to normal menstruation. Of these menstrual abnormalities, heavy menstrual bleeding (HMB), defined objectively as a blood loss of 80 ml or more per menstrual cycle , which is unrelated to pregnancy or known pelvic or systemic disease.

Eligibility

Age

25 - 45 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Regular menstrual cycles with BMI (19-29 kg/m2). Heavy and/or prolonged menstrual bleeding involving at least last three consecutive menstrual cycles.

Exclusion Criteria

•1. Postmenopausal bleeding (over one year since the last menstrual period).
•2. Irregular menses or intermenstrual bleeding.
•3. Organic causes of heavy menstrual bleeding suspected or confirmed by experienced abdominal and transvaginal ultrasound after thorough general and gynecological examination.
•4. Iatrogenic (treatment-related) causes of heavy menstrual bleeding (e.g. non-progestogen-releasing intrauterine contraceptive device, oral contraceptives, other hormonal drug use or anticoagulant agent).
•5. Iron deficiency anemia.
•6. History of chronic diseases known to interfere with menstrual bleeding or prevent the use of any of the listed drugs e.g previous or current thromboembolic disease.

Locations (1)

Ahmed Abbas

Assiut, Cairo Governorate, Egypt

Key Dates

Start Date

November 1, 2017

Primary Completion Date

October 10, 2020

Completion Date

February 10, 2021

Last Updated

June 4, 2021

Enrollment

240

ACTUAL participants

Conditions

Improve Quality of LifeHeavy Menstrual Bleeding

Interventions

combined contraceptive pills (microcept)

DRUG

medroxyprogesterone acetate (progest)

DRUG

mefenamic acid (ponstan forte)

DRUG

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

NCT06634719

Heavy Menstrual Bleeding

View study

NOT_YET_RECRUITING

Evaluating the Reliability and Validity of the Arabic Version of the SAMANTA Questionnaire: A Step Toward Improved Diagnosis of Heavy Menstrual Bleeding

NCT07267611

Heavy Menstrual Bleeding

View study

COMPLETEDNA

Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 4, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause

Inclusion Criteria

Exclusion Criteria

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

Evaluating the Reliability and Validity of the Arabic Version of the SAMANTA Questionnaire: A Step Toward Improved Diagnosis of Heavy Menstrual Bleeding

Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments to Enable Earlier Diagnosis and to Predict Courses of Treatment

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length